Market Size of Egypt Diabetes Drugs Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 414.66 Million |
| Market Size (2029) | USD 480.70 Million |
| CAGR (2024 - 2029) | 3.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Egypt Diabetes Drugs Market Analysis
The Egypt Diabetes Drugs Market size is estimated at USD 414.66 million in 2024, and is expected to reach USD 480.70 million by 2029, growing at a CAGR of 3% during the forecast period (2024-2029).
Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic.
Egypt is the ninth country in terms of Diabetes prevalence worldwide. Currently, as per IDF, about 18.4% of the adult population in Egypt has diabetes. More than 11% of the Egyptian population suffers from diagnosed Type-2 diabetes according to Egypt Youth Association for Health Development. 73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030.
Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the country and is one of the leading causes of premature death, morbidity, and loss of economic growth.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Egypt Diabetes Drugs Industry Segmentation
Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Egypt Diabetes Drugs Market is segmented into drugs. The report offers the value (in USD) for the above segments.
| Insulins | |||||||
| |||||||
| |||||||
| |||||||
|
| Oral Anti-diabetic drugs | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
| Non-Insulin Injectable drugs | |||||||
| |||||||
|
| Combination drugs | |||||
| |||||
|
Egypt Diabetes Drugs Market Size Summary
The Egypt Diabetes Drugs Market is poised for growth, driven by the increasing prevalence of diabetes in the country, which ranks ninth globally in terms of diabetes prevalence. The market is characterized by a significant demand for diabetic drugs, which are essential for managing blood glucose levels and preventing complications associated with the disease. The oral anti-diabetic drugs segment dominates the market due to their efficacy, safety, and cost-effectiveness, making them a preferred choice for treating type 2 diabetes. Initiatives like the Egyptian Government's '100 million Seha' program aim to raise awareness and improve diabetes management, further bolstering market prospects. The market is also witnessing advancements with the introduction of new drugs, such as Empagliflozin and Metformin Hydrochloride, which are designed to enhance glycemic control and reduce cardiovascular risks in diabetic patients.
Metformin, a key player in the market, is expected to maintain its dominance due to its role as a first-line treatment for hyperglycemia in type 2 diabetes and its anti-inflammatory properties. The market landscape is consolidated, with major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca holding significant shares. These companies are actively engaging in strategic mergers and acquisitions to expand their market presence and explore new revenue streams. Despite challenges such as limited healthcare access in rural areas and financial constraints affecting patient care, the government and healthcare providers are working towards improving access and affordability of diabetes treatments. The ongoing developments and strategic initiatives in the market indicate a positive growth trajectory for the Egypt Diabetes Drugs Market over the forecast period.
Egypt Diabetes Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Insulins
-
2.1.1 Basal or Long Acting Insulins
-
2.1.1.1 Lantus (Insulin Glargine)
-
2.1.1.2 Levemir (Insulin Detemir)
-
2.1.1.3 Toujeo (Insulin Glargine)
-
2.1.1.4 Tresiba (Insulin Degludec)
-
2.1.1.5 Basaglar (Insulin Glargine)
-
-
2.1.2 Bolus or Fast Acting Insulins
-
2.1.2.1 NovoRapid/Novolog (Insulin Aspart)
-
2.1.2.2 Humalog (Insulin Lispro)
-
2.1.2.3 Apidra (Insulin Glulisine)
-
-
2.1.3 Traditional Human Insulins
-
2.1.3.1 Novolin/Actrapid/Insulatard
-
2.1.3.2 Humulin
-
2.1.3.3 Insuman
-
-
2.1.4 Biosimilar Insulins
-
2.1.4.1 Insulin Glargine Biosimilars
-
2.1.4.2 Human Insulin Biosimilars
-
-
-
2.2 Oral Anti-diabetic drugs
-
2.2.1 Biguanides
-
2.2.1.1 Metformin
-
-
2.2.2 Alpha-Glucosidase Inhibitors
-
2.2.2.1 Alpha-Glucosidase Inhibitors
-
-
2.2.3 Dopamine D2 receptor agonist
-
2.2.3.1 Bromocriptin
-
-
2.2.4 SGLT-2 inhibitors
-
2.2.4.1 Invokana (Canagliflozin)
-
2.2.4.2 Jardiance (Empagliflozin)
-
2.2.4.3 Farxiga/Forxiga (Dapagliflozin)
-
2.2.4.4 Suglat (Ipragliflozin)
-
-
2.2.5 DPP-4 inhibitors
-
2.2.5.1 Onglyza (Saxagliptin)
-
2.2.5.2 Tradjenta (Linagliptin)
-
2.2.5.3 Vipidia/Nesina(Alogliptin)
-
2.2.5.4 Galvus (Vildagliptin)
-
-
2.2.6 Sulfonylureas
-
2.2.6.1 Sulfonylureas
-
-
2.2.7 Meglitinides
-
2.2.7.1 Meglitinides
-
-
-
2.3 Non-Insulin Injectable drugs
-
2.3.1 GLP-1 receptor agonists
-
2.3.1.1 Victoza (Liraglutide)
-
2.3.1.2 Byetta (Exenatide)
-
2.3.1.3 Bydureon (Exenatide)
-
2.3.1.4 Trulicity (Dulaglutide)
-
2.3.1.5 Lyxumia (Lixisenatide)
-
-
2.3.2 Amylin Analogue
-
2.3.2.1 Symlin (Pramlintide)
-
-
-
2.4 Combination drugs
-
2.4.1 Insulin combinations
-
2.4.1.1 NovoMix (Biphasic Insulin Aspart)
-
2.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
-
2.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
-
-
2.4.2 Oral Combinations
-
2.4.2.1 Janumet (Sitagliptin and Metformin)
-
-
-
Egypt Diabetes Drugs Market Size FAQs
How big is the Egypt Diabetes Drugs Market?
The Egypt Diabetes Drugs Market size is expected to reach USD 414.66 million in 2024 and grow at a CAGR of 3% to reach USD 480.70 million by 2029.
What is the current Egypt Diabetes Drugs Market size?
In 2024, the Egypt Diabetes Drugs Market size is expected to reach USD 414.66 million.
